Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial 'concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma': Individual case review analysis

Abrunhosa-Branquinho Andre N.; Bar-Deroma Raquel; Collette Sandra; Clementel Enrico; Liu Yan; Hurkmans Coen W.; Feuvret Loic; Van Beek Karen; van den Bent Martin; Baumert Brigitta G.; Weber Damien C.

首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial 'concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma': Individual case review analysis

【24h】

Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial 'concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma': Individual case review analysis

机译：RTOG 0834 / EORTC 26053-22054 / NCIC CTG CEC.1 / CATNON杂项试验的放射疗法质量保证“新诊断的非1P / 19Q缺失的内塑性胶质瘤同时和佐剂替替替莫替莫替斯化疗”：个人案例审查分析

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: The EORTC phase III 26053-22054/RTOG 0834/NCIC CTG CEC.1/CATNON intergroup trial was designed to evaluate the impact on concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic gliomas. The primary endpoint was overall survival. We report the results of retrospective individual case reviews (ICRs) for the first patient randomized per institution to detect the compliance with the study protocol.

机译：背景：EORTC阶段III 26053-22054 / RTOG 0834 / NCIC CTG CEC.1 / CATNON族群试验旨在评估新诊断的非1P / 19Q缺失的包塑性胶质瘤的对同时和辅助替替替莫唑族化疗的影响。主要终点是整体存活率。我们报告了追溯个人案例评论（ICRS）的第一个患者，为每机构随机分机检测遵守研究方案。

著录项

来源
《Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology》 |2018年第2期|共7页
作者
Abrunhosa-Branquinho Andre N.; Bar-Deroma Raquel; Collette Sandra; Clementel Enrico; Liu Yan; Hurkmans Coen W.; Feuvret Loic; Van Beek Karen; van den Bent Martin; Baumert Brigitta G.; Weber Damien C.;
展开▼
作者单位

EORTC HQ Brussels Belgium;

Rambam Hlth Care Campus Radiat Oncol Haifa Israel;

EORTC HQ Brussels Belgium;

EORTC HQ Brussels Belgium;

EORTC HQ Brussels Belgium;

EORTC ROG RTQA Strateg Comm Brussels Belgium;

Hop La Pitie Salpetriere Serv Radiotherapie Paris France;

Univ Hosp Leuven Dept Radiat Oncol Leuven Belgium;

Erasmus MC Canc Inst Brain Tumor Ctr Rotterdam Netherlands;

Maastricht Univ Med Ctr Maastricht Netherlands;

ETH Domain Paul Scherrer Inst Ctr Proton Therapy Villigen Switzerland;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Radiotherapy; EORTC; RTQA; Anaplastic glioma; Individual case review; Phase III trial;

机译：放射疗法;EORTC;RTQA;一个包塑性胶质瘤;个人病例审查;第三阶段试验;

相似文献

外文文献

1. Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis [J] . Abrunhosa-Branquinho Andre N., Bar-Deroma Raquel, Collette Sandra, Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology . 2018,第2期

机译：RTOG 0834 / EORTC 26053-22054 / NCIC CTG CEC.1 / CATNON杂项试验的放射疗法质量保证“新诊断的非1P / 19Q缺失的内塑性胶质瘤同时和佐剂替替替莫替莫替斯化疗”：个人案例审查分析
2. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study [J] . van den Bent Martin J., Baumert Brigitta, Erridge Sara C., The Lancet . 2017,第10103期

机译：临时结果由CatNon试验（EORTC研究26053-22054）用同时和佐剂替替替替莫替莫替莫替莫替莫替莫替莫替莫族的临时结果，用于1P / 19Q非共缺陷的粘性胶质瘤：A相，随机，开放标签互动研究
3. RESULTS OF THE INTERIM ANALYSIS OF THE EORTC RANDOMIZED PHASE III CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1P/19Q CO-DELETION, AN INTERGROUP TRIAL [J] . Neuro-Oncology . 2016,第suppla4期

机译：1P / 19Q共删除的无胶质胶质瘤胶体的同时和辅助替莫唑胺EORTC随机化的III期临床试验的中期分析结果
4. Radiotherapy Quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON Intergroup trial concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma: individual case review analysis [O] . André N. Abrunhosa-Branquinho, Raquel Bar-Deroma, Sandra Collette, -1

机译：RTOG 0834 / EORTC 26053-22054 / NCIC CTG CEC.1 / CATNON的放射治疗质量保证组间试验新诊断为非1p / 19q缺失的间变性神经胶质瘤的同时和辅助替莫唑胺化疗：个案回顾分析
5. Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial “concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma”: Individual case review analysis [O] . André N. Abrunhosa-Branquinho, Raquel Bar-Deroma, Sandra Collette, 2018

机译：RTOTHERAPY RTOG 0834 / EORTC 26053-22054 / NCIC CTG CEC.1 / CATNON族群试验“新诊断的非1P / 19Q缺失的内塑性胶质瘤的同时和佐剂替替替替莫唑族化疗”：个人病例审查分析

Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial 'concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma': Individual case review analysis

摘要

著录项

相似文献

相关主题

期刊订阅